Reni Benjamin

OXiGENE Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research report released yesterday, H.C.

Editor Ben Weinberg — August 7, 2014, 11:32 AM EDT

H.C. Wainwright Reiterates Buy On Cesca Therapeutics Following Collaboration Agreement Extension

In a research report released yesterday, H.C.

Editor Ben Weinberg — August 6, 2014, 12:04 PM EDT

La Jolla Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research note released Tuesday, H.C.

Editor Ben Weinberg — August 5, 2014, 3:59 PM EDT

H.C. Wainwright Reiterates Buy On CTI Biopharma Following 2Q14 Earnings Report

In a research report released today, H.C.

Editor Ben Weinberg — August 5, 2014, 3:18 PM EDT

HC Wainwright Reiterates Buy On Celsion Following The Company’s Latest Announcements

Celsion Corp. (CLSN) announced interim data from the ongoing Phase 2 DIGNITY trial of ThermoDox in Recurrent Chest Wall Breast Cancer (RCWBC), where …

Editor Ben Weinberg — July 29, 2014, 9:44 AM EDT

H.C. Wainwright Reiterates Buy On Agenus Following 2Q14 Results

In a research report issued this morning, H.C.

Ben Mahaney, Editor — July 25, 2014, 9:02 AM EDT

H.C. Wainwright Reiterates Buy On Celsion Following Meeting With Management

In a research report issued today, H.C.

Ben Mahaney, Editor — July 16, 2014, 3:28 PM EDT

Cesca Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research note released earlier today, H.C.

Editor Ben Weinberg — July 8, 2014, 11:10 AM EDT

H.C. Wainwright Reiterates Buy On Spectrum Pharmaceuticals Following Lymphoma Drug Approval

In a research note issued today, H.C.

Editor Ben Weinberg — July 7, 2014, 8:46 AM EDT

H.C. Wainwright Reiterates Buy On Agenus Following Phase 2 Data From Prophage Vaccine

In a research note released Tuesday, H.C.

Editor Ben Weinberg — July 2, 2014, 10:08 AM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts